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Abstract
Background: Young people who have social disability associated with severe and complex mental health problems
are an important group in need of early intervention. Their problems often date back to childhood and become
chronic at an early age. Without intervention, the long-term prognosis is often poor and the economic costs very large.
There is a major gap in the provision of evidence-based interventions for this group, and therefore new approaches to
detection and intervention are needed. This trial provides a definitive evaluation of a new approach to early
intervention with young people with social disability and severe and complex mental health problems using social
recovery therapy (SRT) over a period of 9 months to improve mental health and social recovery outcomes.
Methods: This is a pragmatic, multi-centre, single blind, superiority randomised controlled trial. It is conducted in three
sites in the UK: Sussex, Manchester and East Anglia. Participants are aged 16 to 25 and have both persistent and severe
social disability (defined as engaged in less than 30 hours per week of structured activity) and severe and complex
mental health problems. The target sample size is 270 participants, providing 135 participants in each trial arm.
Participants are randomised 1:1 using a web-based randomisation system and allocated to either SRT plus optimised
treatment as usual (enhanced standard care) or enhanced standard care alone. The primary outcome is time use,
namely hours spent in structured activity per week at 15 months post-randomisation. Secondary outcomes assess
typical mental health problems of the group, including subthreshold psychotic symptoms, negative symptoms,
depression and anxiety. Time use, secondary outcomes and health economic measures are assessed at 9, 15 and
24 months post-randomisation.
Discussion: This definitive trial will be the first to evaluate a novel psychological treatment for social disability and
mental health problems in young people presenting with social disability and severe and complex non-psychotic
mental health problems. The results will have important implications for policy and practice in the detection and early
intervention for this group in mental health services.
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Background
It is widely recognised that most socially disabling chronic
and severe mental health problems begin in adolescence,
with 75% of all severe and chronic mental illnesses emer-
ging between the age of 15 and 25 years [1, 2]. Retrospect-
ive studies have consistently shown that severe mental
illness is often preceded by social decline, which often be-
comes stable, and that such pre-morbid social disability is
predictive of the long-term course of the disorder [3–9].
Between 3% and 5% of adolescents present with complex
mental health problems associated with social disability [2].
The young people at highest risk of long-term social dis-
ability present with emerging signs of social decline, in as-
sociation with low level psychotic symptoms, emotional
and behavioural disorder, and often accompanied by sub-
stance misuse problems and risk of harm to self and others
[1, 2]. Social disability in young people with severe mental
health problems can be operationally defined behaviourally
as low activity, or time spent, in social and economic do-
mains [10]. The target population at high risk of long-term
social disability and chronic mental health problems are
therefore young people with severe and complex mental
health problems who are not in education employment and
training (NEET) and who are inactive and socially with-
drawn. The severe and complex mental health problems
typically include severe depression and anxiety symptoms
often, but not always, accompanied by sub-threshold psych-
otic symptoms (paranoia and anomalous experiences) and
frequently other symptomatic comorbidities (obsessive
compulsive disorder, body dysmorphic symptoms and so
on). This includes cases that meet formal diagnostic criteria
for at risk or ultra-high risk for psychosis who are with-
drawn and socially and economically inactive, but it does
not exclude cases who have other types of severe and com-
plex mental health problems associated with social disabil-
ity. From the perspective of clinical staging [11], these may
be regarded as severe cases at stage 1b having attenuated
syndromes with mixed and ambiguous symptomatology
and severe functional impacts.
The economic costs of not addressing mental health
problems associated with social disability at an early stage
are high [12]. Persistent mental health problems associated
with social disability in young people often do not resolve
naturally and may persist across the life course, resulting in
severe distress and long-term social disability, as well as
high costs in terms of use of health, social and other ser-
vices [1, 2]. Health economic modelling of lifelong costs in
this area are still emerging; however, one recent estimate
suggests that mental health problems in childhood and
adolescence can result in a 28% reduction in economic ac-
tivity at age 50, with consequences across domains of mari-
tal satisfaction, self-esteem and quality of life leading to a
£388,000 lifetime loss per person [13, 14]. Young people
who have a combination of severe and persistent mental
health needs and who are socially disabled present with
problems that have the highest lifelong burden [14].
Despite poor outcomes and the high cost of disorders
leading to social decline, young people with complex needs
frequently do not access treatment. Recent estimates sug-
gest that fewer than 25% of young people and their families
who have needs gain access to specialist mental health ser-
vices [15, 16]. Recent reports have highlighted that there is
a major gap in identifying and managing severe and com-
plex mental health problems in young people, particularly
in those at risk of social disability [14–19]. Several UK
NICE guidelines have highlighted this issue, including those
for social anxiety [20] and depression [21], and the NICE
guidelines on psychosis and schizophrenia in children and
young people [17].
Young people with severe and complex mental health
problems and who are socially disabled often fall between
the net and do not access treatment. In the UK, such indi-
viduals tend not to be suitable for, or respond to, short-
term evidence-based therapies for discrete mental health
problems, such as cognitive behavioural therapy (CBT) for
anxiety, depression and conduct disorder that are available
via the Improving Access to Psychological Therapies initia-
tive. However, they do not meet diagnostic criteria for spe-
cialist first episode psychosis services, for which there is
now considerable evidence of benefits on social functioning
[22–24]. If help seeking, their pathways to care are often di-
verse and, while some may receive care from Child and
Adolescent Mental Health Services and Adult services,
others are regarded as not meeting the diagnostic thresh-
olds for entry or may disengage from services that do not
offer assertive outreach. Many cases only have support from
primary care despite having severe and complex mental
health needs and social disability. The most systematic ser-
vice provision is often outside mental health services in
statutory and voluntary sector provision for young people
who are NEET. In these services, the focus is primarily on
obtaining employment and thus the mental health prob-
lems that present barriers to activity, work, education and
training may not be recognised [25]. However, the degree
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to which NEET status is associated with mental health
problems is being increasingly recognised [26–31]. Detec-
tion of such cases therefore needs to focus on screening of
mental health problems of young people who have links
with NEET services and who are under primary mental
health care alongside seeking referrals from those referred
into Child and Adolescent Mental Health Services and
Adult services. Cases may also be detected in services for
those in the at risk mental state (ARMS) for psychosis
group, where these are present.
Current evidence for effective interventions to address so-
cial disability amongst young people in the early course of
severe mental illness is limited [3]. A series of studies have
been undertaken that have aimed to identify cases at ultra-
high risk (UHR) of poor long-term outcome associated with
severe mental illness, focusing predominantly on risk of
psychosis [32–37]. These UHR studies have shown that it is
possible to establish services to identify and treat cohorts of
young people who can be identified as having ARMS using
defined operational criteria and structured assessment tools
[38]. Furthermore, these studies have consistently identified
that those who are at the highest risk of poor outcomes are
young people who present with social decline as well as
sub-threshold psychotic symptoms [39, 40]. However, the
focus of treatment trials in the UHR group has been on
prevention of first episode psychosis, not social disability. A
recent meta-analysis of intervention trials in this group
found a reduction in risk of psychosis with specific treat-
ments but no improvement in functioning compared to
control conditions [41].
Systematic reviews of CBT for psychosis have consist-
ently shown moderate effect size improvements in social
disability where this has been assessed as a secondary out-
come [42, 43]. However, these studies have predominantly
been carried out amongst participants with chronic disor-
ders rather than emerging problems. The feasibility of
using CBT with young people who are at UHR of psych-
osis has been demonstrated by the Early Detection and
Intervention Evaluation for People at Risk of Psychosis
(EDIE 2) multicentre study [44], which has shown reduc-
tions in severity of psychotic symptoms. However, the pri-
mary focus of the therapy in EDIE 2 and other studies of
cognitive therapy in UHR [17] was symptom reduction
[45] and this approach neither targeted nor had a signifi-
cant benefit on social disability. The present trial moves
on from EDIE 2 by (1) focussing on a group of young
people who are UHR and have problems defined by social
disability (low structured activity levels) and (2) using a
multi-systemic intervention that specifically aims to ad-
dress social disability.
A previous multi-systemic social recovery therapy
(SRT) intervention trial (Improving Social Recovery in
Early Psychosis; ISREP) was carried out with a group of
young people who had established chronic and severe
social disability up to 8 years after a first episode of
psychosis. This demonstrated gains in structured activity
and hope as well as reductions in symptoms [46]. Health
economic benefits were also demonstrated [47]. How-
ever, the trial was small and there was a high level of un-
certainty associated with these estimates. A more recent
study has confirmed that SRT can improve the activity
of young people with first episode psychosis who had
persistent social recovery problems [48], the effect was
clearest at post treatment showing earlier social recovery
and there were also promising indications of persistence
of the effect albeit limited by missing data at follow-up.
The SRT intervention tested in the present trial (PROD-
IGY) has been refined from experience in these previous
studies to be applied to a novel population – socially dis-
abled young people with severe and complex mental
health problems [49]. Qualitative studies have confirmed
the acceptability and satisfaction of participants with
both PRODIGY trial procedures and SRT [50, 51]. Our
approach is consistent with the goals of the recovery
movement in that the focus is not just on symptoms but
on wider outcomes, including social activities, work and
education [52, 53]. PRODIGY will be the first trial to
specifically test the effectiveness of an intervention that
aims to improve both social recovery and mental health
outcomes amongst a high-risk population of young
people presenting with social disability and severe and
complex mental health problems.
The present study aims to undertake a definitive ran-
domised controlled trial (RCT) to determine the clinical
and cost-effectiveness of SRT compared to enhanced
standard care (ESC) in young people who present with
social disability and severe and complex non-psychotic
mental health problems, and who are at risk of long-
term social disability and mental illness.
Primary hypothesis
In young people who are socially disabled and have severe
and complex non-psychotic mental health problems, SRT
will be superior to ESC in improving social recovery (as
measured by hours in structured activity assessed on the
time use survey), at 15 months post-randomisation.
Secondary hypotheses
First, that SRT will be superior to ESC in terms of cost-
effectiveness and, second, that SRT will be superior to
ESC in effects on mental health symptoms.
Methods
Trial design
PRODIGY is a pragmatic, multi-centre, single blind, paral-
lel, superiority RCT comparing the clinical and cost-
effectiveness of SRT delivered over a 9-month period plus
optimised treatment as usual (ESC) against ESC alone.
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Participants are young people (aged 16 to 25 years) with se-
vere and complex mental health problems and showing
early signs of persistent social disability. The primary out-
come is time use (weekly hours in structured activity) at
the primary time point of 15 months. Time use and sec-
ondary outcomes will be evaluated at 9 and 15 months
post-randomisation with 15 months as the primary end-
point; there will be a further assessment at 24 months post-
randomisation to assess the persistence of the effect.
Intervention
SRT
The intervention is SRT plus ESC delivered by trial thera-
pists who are clinical psychologists or qualified CBT ther-
apists trained in the intervention by the first and second
authors (DF, PF). SRT is described in a therapy manual
[49]. SRT is delivered individually in face-to-face sessions
(Median = 15 sessions) across 9 months and may involve
interim telephone and email contact. Sessions take place
in participants’ homes, National Health Services (NHS)
premises, community and public locations. All sessions,
except where conducted in public locations, are audio-
recorded with participant consent.
SRT is based on a CBT model which suggests that social
disability evolves as a result of lifestyle patterns of low activ-
ity, which are adopted as functional behavioural patterns of
avoidance and maintained by lack of hope, a reduced sense
of agency and low motivation. The intervention involves
promoting a sense of agency, hope and motivation, and en-
couraging activity while managing sub-threshold psychotic
symptoms where present, non-psychotic mental health
problems and neurocognitive functioning difficulties. The
approach combines multi-systemic working with the use of
specific CBT techniques. Multi-systemic working involves
working with participants’ relatives and employment or
education providers. Trial therapists adopt assertive out-
reach youth work principles and also draw from successful
social and vocational interventions, such as supported edu-
cation and employment interventions.
The intervention involves three stages that are flexibly
tailored to each participant’s goals and problems:
 Stage 1 involves assessment and developing a
formulation of the person’s difficulties and barriers to
social recovery. This often involves validation and
acceptance of real barriers, threats and difficulties,
while focusing on promoting hope for social recovery.
 Stage 2 involves identifying and working towards
medium- to long-term goals guided by a systemic
formulation of barriers to recovery. A particularly
important aspect of this is identifying specific path-
ways to meaningful new activities and values. Where
relevant, this includes referral to appropriate voca-
tional agencies, or alternatively direct liaison with
employers or education providers. Additional spe-
cific techniques used in this stage include cognitive
work promoting a sense of agency, consolidating a
positive identity and addressing feelings of stigma
and negative beliefs about self and others.
 Stage 3 involves the active promotion of social
activity, work, education and leisure linked to
meaningful goals, while managing symptoms. This
involves specific cognitive behavioural techniques
involving managing symptoms while promoting
activity using behavioural experiments.
ESC
The control comparator is ESC alone. There is no
restriction on access to existing NHS standard treat-
ment for young people with non-psychotic severe
and complex problems and social disability. ESC can
include provision of short-term individual and family
psychological therapies, medication management,
support and monitoring within primary or secondary
mental health services. Participants may also receive
a range of education, social, training, vocational and
youth work interventions from a variety of statutory
and non-statutory service providers (including social
services, voluntary agencies, employment and educa-
tion providers). ESC also involves the provision of a
Best Practice Manual for standard treatment from
the trial team to the referrer and usual care provider
(if not the referrer), which summarises good practice,
including referral to mental health services and
medication management where appropriate. The Best
Practice Manual has been produced by monitoring
and mapping service contacts received across a range
of services in the population of interest.
Participants and referrers and/or the usual clinical team
(with participant consent) also receive assessment feed-
back from the trial team pertaining to clinical and social
circumstances. Assessments identify any risks to self or
others and these are communicated to the referring clini-
cians to facilitate appropriate management. As identified
in our qualitative studies [50, 51], participation in the trial
in both trial arms is experienced by many participants as
beneficial and an enhanced intervention. The Best Practice
Manual and the approach of the trial team has been sup-
ported by service user groups and steering groups over-
seeing youth mental health provision in each of the
regions, and its delivery has been well received by partici-
pating services, with referrers keen to involve participants
in both treatment and control arms.
Outcomes
Primary outcome
The primary outcome is time use (hours per week en-
gaged in structured activity) measured at the 15 months
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post-randomisation. This assessment is derived from the
Office of National Statistics Time Use Survey interview
[54], adapted for use with a clinical population [10].
Number of hours per week engaged in structured activ-
ity includes time spent in both constructive economic
activity, e.g. paid and voluntary work, education, child-
care, housework and chores, and in structured activity,
including leisure and sports.
Secondary outcomes
Secondary outcomes focus on typical mental health
problems of this group and include levels of attenuated
psychotic symptoms and associated psychopathology using
the Comprehensive Assessment of At Risk Mental States
(CAARMS) interview [38], change in diagnostic status from
Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders, Version Four [55], The Social
Interaction Anxiety Scale [56] and Beck Depression
Inventory-II [57], and the Scale for the Assessment of Nega-
tive Symptoms [58]. The assessments and the timing are
outlined in the SPIRIT figure (Fig. 1). All outcomes will be
assessed at baseline and again at 9, 15 and 24 months post-
randomisation. The neurocognitive assessments are only
assessed at baseline and 15 months post-randomisation. See
the Additional file 1 for the SPIRIT checklist.
Mediators include the Acceptance and Avoidance II
scale [59], Meaning in Life Questionnaire [60], Trait Hope
Scale [61], Schizotypal Symptoms Inventory [62] and Brief
Core Schema Scales [63].
Neurocognitive function will be assessed as a moderator
and includes Logical Memory I subtest of the Wechsler
Memory Scale, Third Edition [64] and Controlled Oral
Word Association Test [65].
Other outcomes include Alcohol Use Disorders Identifi-
cation Test [66], Drug Use Disorders Identification Test
[67] and the Beck Hopelessness Scale [68].
Health economic outcomes
Costs will be estimated from the perspective of the NHS
and personal social services (PSS) using the Health Ser-
vice Resource Use Questionnaire [69] and quality of life
will be assessed via the EuroQol-5D-3 L [70].
Adverse events
All serious adverse events and adverse events will be
categorised and recorded from the point of randomisa-
tion until completion of the final follow-up assessment.
All events will be reported to sponsor, local trial site,
clinical trials unit (CTU), and trial oversight committees
(Data Monitoring and Ethics Committee and Trial Steer-
ing Committee). Serious adverse events will be onward
reported to the NHS ethics committee as appropriate.
Participants
Inclusion criteria
1. Young people aged 16 to 25 years with severe and
complex mental health problems and showing early
signs of persistent social disability.
2. Presence of impairment in social and occupational
function indicated by patterns of structured and
constructive economic activity of less than 30 hours
per week and a history of social impairment problems
lasting for a period of longer than 6 months.
3. Presence of severe and complex mental health
problems defined operationally as:
a) having attenuated psychotic symptoms which meet
criteria for an ARMS, or
b) having severe and complex mental health problems
which score 50 or below on the Global Assessment
of Function Scale (which indicates the presence of
severe symptoms of at least two of depression,
anxiety, substance misuse, behavioural or thinking
problems, or subthreshold psychosis to the degree to
impair function) with at least moderate symptoms
persisting for longer than 6 months.
Exclusion criteria
1. Age below 16 or above 25 years.
2. Active positive psychotic symptoms or history of
first episode psychosis.
3. Severe learning disability problems (though mild to
moderate learning difficulties will not be excluded).
4. Disease or physical problems likely to interfere with
capacity to take part in interventions and
assessments.
5. Non-English speaking to the degree that the
participant is unable to fully understand and answer
assessment questions or give informed consent.
Recruitment and procedure
Three centres are involved in the study. Participants are
drawn from secondary mental health care settings including
outpatient youth mental health, early detection, and early
intervention services, youth, social and educational services,
and primary care mental health services in the three centres
in East Anglia (Norfolk and Suffolk), Sussex and Greater
Manchester. Potential participants from these services who
consent to be contacted about the trial are referred by a
professional to the trial team and provided with a trial in-
formation sheet. Research assistants (RAs) then meet with
the potential participant in person to obtain written in-
formed consent and perform the screening assessments
(Fig. 1). Potential participants categorised as ‘screen failures’
are permitted to re-screen at a later date if appropriate. Po-
tential participants eligible at screen are invited to complete
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Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT): Schedule of enrolment, interventions and assessments
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the baseline assessment and, upon doing so, are rando-
mised. All randomised participants are invited to
undergo three post-randomisation follow-up assess-
ments at 9, 15 and 24 months (Fig. 1). Interventions are
provided from randomisation allocation until com-
mencement of the 9 month post-randomisation follow-
up assessments (Fig. 1).
Sample size
The target sample size is 270 participants, providing 135
participants in each trial arm. The primary outcome is
hours per week in structured activity on the time use
survey [10, 54] at 15 months, which is likely not to fol-
low a normal distribution but could have a positive
skew. Analyses will therefore most likely use logarith-
mically transformed data. The sample size is based upon
an effect size of 0.4 standard deviations being considered
a minimum clinically significant benefit. A total of 270
participants would provide greater than 90% statistical
power to detect a 0.4 standard deviation effect size; a
total of 200 participants (i.e. even accounting for greater
than 25% loss to follow-up) would provide 80% statis-
tical power for the same effect size. A total of 100 partic-
ipants were recruited in the internal pilot phase, with a
target sample size of 170 to be recruited in the current
non-pilot extension phase.
Randomisation
Following pre-trial assessments, consenting participants
are randomised to trial arms stratified by age in years
(16–19, 20–25); site (Sussex, East Anglia, Manchester);
severity of social disability (low functioning = 16 to
30 hours of structured activity per week, very low func-
tioning = 0–15 hours of structured activity per week),
and meeting symptomatic criteria for ARMS or not. A
remote randomisation service assigns allocation to
groups coordinated by the Norwich CTU. Allocation is
by pre-set lists of permuted blocks with randomly dis-
tributed block sizes (agreed with the Trial Statistician).
The lists are generated by the Data Management Team
in Norwich CTU.
The allocation process is web-based, managed as part
of the Trial Data Management System (TDMS). The se-
quence is hidden from TDMS users. Once allocated, the
details are emailed to nominated individuals at the trial
site to enable the allocation of treatment to be imple-
mented. The allocation is not exposed to any other users
of the database or other individuals.
Following completion and scoring of all baseline as-
sessments per individual participant, site staff enter
stratification information into the electronic database.
Once submitted, an email is generated to the site staff to
issue a participant number and inform that a participant
has been randomised. Nominated members of the team
(Trial Manager, Co-ordinators and Trial Therapists in
the individual sites) receive an email detailing the alloca-
tion of said participant. This is logged by the Site Coord-
inator (locally) and Trial Manager (centrally) and the
allocated Trial Therapists are informed to contact the
participant (for those randomised to SRT plus ESC). Par-
ticipants randomised to ESC alone are contacted by let-
ter. The participant’s General Practitioner, referrer and
usual care provider (if not the referrer) are informed of
the allocation by a trial therapist or site co-ordinator.
RAs do not have access to the allocation at any time
during the trial.
Blinding
Research staff collecting follow-up data are blinded to
group allocation. This is maintained using a range of
procedures. Following allocation, all participants in the
trial, their relatives, their referrer and clinical team (if
applicable) are asked not to reveal the allocation to the
RAs. Participants, and any attending relatives or profes-
sionals if applicable, are also asked at the beginning of
each assessment interview not to disclose the allocation.
Outside of the assessments, RAs are shielded from dis-
cussion of participants in trial forums where the possi-
bility of determining the allocation could occur. A
system of web-based data entry ensures that RAs do not
have access to information in the database that would
reveal the allocation. Data entered into TDMS by trial
therapists that might inadvertently lead to unblinding is
hidden from non-trial therapist users. To test the suc-
cess of blinding, the blind assessor is asked to guess the
allocation group for each participant at the end of the
final assessment.
All issues with blinding are recorded and reported
to the site co-ordinator and trial manager. Reported
issues with blinding are managed to maintain blind
outcome assessments by reallocating ‘blind’ RAs to
collect and score trial data. Promotion of ‘blind’
awareness and education continues throughout the
trial, including communicating to administrative staff,
referrers and clinical teams to minimise the occur-
rence of issues with the blind in addition to remind-
ing participants and their relatives.
Measurement quality
All assessors receive expert training in administration of
outcome measures at least every 6 months. All assessors
receive local site supervision in administration of out-
come measurements for all participants screened at least
weekly and central supervision with the trial manager at
least fortnightly. Concordance for primary and key sec-
ondary outcome ratings is assessed every 2 months
across all trial assessors, site co-ordinators and the trial
manager in all three trial sites.
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Intervention adherence
All trial therapists receive expert training in intervention
delivery at least every 6 months. All therapists receive
local site supervision with site co-ordinators and separ-
ate central supervision at least monthly. Concordance
ratings of intervention adherence and competence (using
the Cognitive Therapy Rating Scale Revised [71]) are ob-
tained from all trial therapists at least every 2 months.
Statistical methods
The primary analysis will compare SRT plus ESC with
ESC alone on hours spent in structured activity per week
at 15 months post-randomisation. The primary analysis
will be on the intention-to-treat principle, i.e. all partici-
pants will be followed up for data collection irrespective
of adherence to treatment and will be analysed accord-
ing to group allocation rather than intervention received.
Assuming a normal (or corrected to normal) distribu-
tion, a linear model will be constructed. This will include
recruiting site (as a random factor), weekly structured
activity hours at baseline (as a covariate) and any factors
considered prognostic and determined in advance of any
analysis, together with treatment arm as a fixed effect.
The primary intention-to-treat analysis is intended to
provide inferences regarding the effectiveness of the
intervention overall, not to provide inferences regarding
the causal effect of the intervention itself, but on the
intervention as deployed in ‘real life’.
Statistical significance will be set at the conventional
(two-tailed) 5% level and all parameter estimates will be
presented with 95% confidence intervals. Analyses will be
carried out by the trial statistician blinded to group identity
(i.e. ‘subgroup’ blind). There are no plans for interim effi-
cacy or subgroup analyses. Appropriate techniques to man-
age missing data will be used depending upon the nature
and extent of missing data and analysis will also take ac-
count of clustering effects with regard to individual thera-
pists. These and other more detailed aspects of the analysis
plan are set out formally in the Statistical Analysis Plan held
by the Norwich CTU.
The main measure of outcome in the economic analysis
will be the EuroQol-5D-3 L [70]. This will enable a cost-
utility analysis to be conducted, where the incremental
Quality Adjusted Life Year gain associated with SRT com-
pared to ESC will be estimated over the 15-month trial
period. Costs will be estimated from the perspective of the
NHS and PSS, including the cost of the intervention
(based on information from service providers) and other
NHS and PSS costs using a (self-reported) modified ver-
sion of the client services receipt inventory [69]. Cost-
effectiveness analyses will also be performed, where the ef-
fectiveness of SRT compared to ESC will also be assessed
in relation to activity (time use) and symptoms
(CAARMS). Analyses will be undertaken in order to
estimate both the incremental cost and incremental effect
associated with SRT compared to treatment as usual (this
within-trial analysis will be undertaken for a 15-month
follow-up period as part of the primary analysis, a 24-
month follow-up analysis is also planned).
Recruitment
Internal pilot phase
Between January 2013 and February 2014, 100 partici-
pants were recruited and randomised. By end of March
2016, 24 month follow-up assessment data had been col-
lected from these participants. These 100 participants
will be combined with those recruited in the substantive
extension phase, providing the full sample.
Substantive non-pilot extension phase
The substantive extension target for recruitment is 170
participants recruited and randomised. Recruitment began
September 2015.
Discussion
This definitive trial will be the first to specifically ad-
dress both social disability and mental health problems
amongst a vulnerable and high-risk population of
young people presenting with social disability and se-
vere and complex non-psychotic mental health prob-
lems. This is a group who are underrepresented in
research, underserved by current mental health services
and treatments, and are at risk of lifelong social disabil-
ity and severe mental health problems without effective
intervention. The trial will provide an essential evi-
dence base for developing interventions for young
people with severe and complex mental health prob-
lems who have social disability characterised by inactiv-
ity in social and economic domains and social
withdrawal. The primary follow-up assessments at post-
Table 1 Changes to protocol
Area Change
Trial documentation Provision of crisis cards and summary
report of assessments to participants
Measurement of outcome Changes to assessment battery; addition
of Structured Clinical Interview for
Diagnostic and Statistical Manual of
Mental Disorders, Version Four, reduction
in neurocognitive battery, reduction from
full CAARMS to short version, addition of
the Alcohol Use Disorders Identification
Test and the Drug Use Disorders
Identification Test
Time point of measurement Addition of 24-month follow-up assess-
ment point
Sponsorship Sussex Partnership NHS Foundation Trust
replaced Norfolk and Suffolk NHS
Foundation Trust as trial sponsor
No deviations from the protocol have been recorded
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treatment and at 15 months will be completed at the
end of 2018 and the final 24-month follow-up will be
completed in 2019.
Protocol changes
The amendments made to the trial protocol since com-
mencement of the trial are shown in Table 1.
Trial status
Trial recruitment is active and ongoing.
Additional file
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